DAX-0,41 % EUR/USD+0,18 % Gold+0,08 % Öl (Brent)+0,60 %

YTEN - Yield10 Bioscience, Inc - Research License deal mit Monsanto


ISIN: US98585K2015 | WKN: A2DSS1 | Symbol: YTEN
0,150
$
04.12.19
AMEX
-16,67 %
-0,030 USD

Beitrag schreiben

Begriffe und/oder Benutzer

 

Bin heute hier eingestiegen. Sieht interessant aus. Insbesondere der research license deal mit Monsanto.

Im folgenden zwei News Releases aus jüngster Vergangenheit:

Yield10 Bioscience Grants Research License to Monsanto to Evaluate Two Novel Yield Traits in Soybean
GlobeNewswire•December 11, 2017


WOBURN, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (YTEN) announced today that it has granted a non-exclusive research license to Monsanto Company to evaluate its novel C3003 and C3004 yield traits in soybean. Under the license, Monsanto plans to research both traits within its soybean pipeline as a strategy to improve plant yields. Yield10 Bioscience is focused on "building better plants" by developing proprietary, breakthrough technologies that produce higher yields in major food and feed crops to enhance global food security using lower inputs of land, water and fertilizer.
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…

Yield10 Bioscience Announces Pricing of $12.6 Million Public Offering
GlobeNewswire•December 19, 2017


WOBURN, Mass., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (YTEN) today announced the pricing of an underwritten public offering of units for gross proceeds of $12.6 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Yield10 Bioscience.

The offering is comprised of 3,828,000 Class A Units, priced at a public offering price of $2.25 per unit, with each unit consisting of one share of common stock, a five-year warrant to purchase one share of common stock at an exercise price of $2.25 per share, and a nine-month warrant to purchase 0.5 share of common stock at an exercise price of $2.25 per share, and 3,987 Class B Units, priced at a public offering price of $1,000 per unit, with each unit consisting of one share of preferred stock, having a conversion price of $2.25, five-year warrants to purchase 445 shares of common stock with an exercise price of $2.25 per share, and nine-month warrants to purchase 223 shares of common stock with an exercise price of $2.25 per share. The conversion price of the preferred stock issued in the transaction and the exercise prices of the warrants are fixed and do not contain any variable pricing features or any price based anti-dilutive features. The preferred stock issued in this transaction includes a beneficial ownership blocker but has no dividend rights (except to the extent that dividends are also paid on the common stock), liquidation preference or other preferences over common stock, and, with certain exceptions, has no voting rights. The securities comprising the units are immediately separable and will be issued separately. The closing of the offering is expected to take place on or about December 21, 2017, subject to the satisfaction or waiver of customary closing conditions.
https://yield10bioscienceinc.gcs-web.com/news-releases/news-…
Link presentation Yield10 Bioscience Third Quarter 2017 Earnings Call
Nov 9, 2017
http://ir.yield10bio.com/static-files/c2f232f8-fee1-4f74-941…

Seite 13 value creation

Seite 15 upcoming milestones
Hallo zusammen, bin neu auf den Wert aufmerksam geworden. Der Kurs war ja schon Mal deutlich höher. Wie kommt der tiefe Fall zu Stande?
ich war auch kurz vor dem einstieg in Yiel10 Bioscience Inc., bis mir hier aufgefallen ist, dass die bude nur den namen (vorher Metabolix) und das geschäftsmodell geändert hat.

sehr suspekt...
Habe heute hier wieder eine erste Position aufgebaut. Die Aktie ist sehr volatil und kann schnell auf $3 steigen. Cash reicht bis nächstes Jahr. Bis dahin werden meiner Ansicht nach genug News kommen, die für einen Kursanstieg sorgen werden. Time will tell...

http://ir.yield10bio.com/news-releases/news-release-details/…
"...the Company anticipates that its current cash resources will be sufficient to fund operations and meet its obligations for at least the next twelve months."
Company presentation:
https://www.yield10bio.com/sites/default/files/YTEN_Investor…

„Has significant, near-term milestones in major row crops
• Data from field tests of C3003 in Camelina, canola and soybean expected in 2018
• Progressing oil enhancing traits using CRISPR genome editing“


Beitrag zu dieser Diskussion schreiben